Media Pack
News

Current Edition

Volume 16 Issue 3
 
 
Regional News

Abzena nabs $65M to bolster manufacturing and research services on both sides of the pond

Roughly one year after dropping designs on a $200 million biologics plant in North Carolina, antibody-drug conjugate specialist Abzena has snared a fresh round of fun...
13 April 2022 Regional News Abzena | antibody
Continue Reading →
Regional News

Amid COVID’s latest surge, Regeneron and Eli Lilly score new antibody supply deals with the U.S.

During a call with analysts last month, Regeneron said it didn’t expect to record additional sales of its COVID-19 antibodies to the United States this year. But les...
16 September 2021 Regional News antibody | COVID
Continue Reading →
news

argenx reports positive topline results from Phase 2 proof-of-concept trial of ARGX-113 (efgartigimod) in generalized myasthenia gravis

argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment o...
13 December 2017 news antibody | autoimmune
Continue Reading →
news

Sanofi and Regeneron announce positive topline pivotal results for PD-1 antibody cemiplimab in advanced cutaneous squamous cell carcinoma

Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive topline results from a pivotal Phase 2 clinical study of cemiplimab in 82 patients ...
13 December 2017 news antibody | BLA
Continue Reading →
 
 
 

jcs-white.png

Journal for Clinical Studies

Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.

Facebook Linkedin
Journal For Clinical Studies © 2024, All Rights Reserved – Powered by Teksyte